- Home
- BLX vs JANX Comparison
BLX vs JANX Comparison
Compare BLX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLX
- JANX
- Stock Information
- Founded
- BLX 1977
- JANX 2017
- Country
- BLX Panama
- JANX United States
- Employees
- BLX N/A
- JANX N/A
- Industry
- BLX Commercial Banks
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- BLX Finance
- JANX Health Care
- Exchange
- BLX Nasdaq
- JANX Nasdaq
- Market Cap
- BLX 1.7B
- JANX 1.4B
- IPO Year
- BLX N/A
- JANX 2021
- Fundamental
- Price
- BLX $47.67
- JANX $24.05
- Analyst Decision
- BLX
- JANX Strong Buy
- Analyst Count
- BLX 0
- JANX 10
- Target Price
- BLX N/A
- JANX $79.50
- AVG Volume (30 Days)
- BLX 106.5K
- JANX 659.2K
- Earning Date
- BLX 10-28-2025
- JANX 11-05-2025
- Dividend Yield
- BLX 5.17%
- JANX N/A
- EPS Growth
- BLX 12.91
- JANX N/A
- EPS
- BLX 5.97
- JANX N/A
- Revenue
- BLX $306,166,000.00
- JANX $439,000.00
- Revenue This Year
- BLX $15.00
- JANX N/A
- Revenue Next Year
- BLX $5.52
- JANX $591.60
- P/E Ratio
- BLX $8.09
- JANX N/A
- Revenue Growth
- BLX 12.96
- JANX N/A
- 52 Week Low
- BLX $29.95
- JANX $21.97
- 52 Week High
- BLX $48.38
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- BLX 64.89
- JANX 49.56
- Support Level
- BLX $45.97
- JANX $23.62
- Resistance Level
- BLX $48.38
- JANX $25.35
- Average True Range (ATR)
- BLX 0.77
- JANX 1.16
- MACD
- BLX 0.05
- JANX 0.15
- Stochastic Oscillator
- BLX 75.77
- JANX 51.57
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.